Protalix BioTherapeutics, Inc. (PLX) Stock: A Good Pick In The Biotech Space?


Protalix BioTherapeutics, Inc. (PLX) is falling in the market today. The company, one that is focused in the biotech industry, is presently trading at $0.23 after tumbling -37.78% so far in today’s session. As it relates to biotechnology companies, there are several factors that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines surrounding PLX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 07:30AM Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates
06:05AM Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update
Aug-01-19 10:32AM Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week’s Release
Jul-29-19 04:01PM Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019
07:00AM Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer

However, when making a decision with regard to investing, investors should take a look at far more than news, this is especially the case in the generally speculative biotechnology space. Here’s what’s happing when it comes to Protalix BioTherapeutics, Inc..

Performance Trends That We’ve Seen From PLX

While a move down on a single session, like the move that we’re seeing from Protalix BioTherapeutics, Inc. might make some investors upset, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It’s generally smart to take a look at trends just a single trading day. When it comes to PLX, here are the trends that investors have experienced:

  • Weekly – In the past week, PLX has generated a change in price in the amount of -38.19%.
  • Past 30 Days – The monthly performance from Protalix BioTherapeutics, Inc. works out to -48.39%.
  • Past 3 Months – In the last quarter, the stock has produced a return of -43.23%
  • Past Six Months – Over the last six months, we’ve seen a performance of -50.63% from the stock.
  • This Year So Far – Since the the last trading session of last year PLX has produced a return on investment of -26.98%.
  • Full Year – Finally, throughout the past full year, investors have seen a change of -53.68% out of PLX. In this period, the stock has traded at a high price of -72.64% and a low of -15.89%.

Rations That Investors Should Consider

Digging into a few key ratios associated with a company can provide traders a look of just how risky and/or rewarding a stock pick may be. Below are a few of the key ratios to think about when looking at PLX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it shows that more investors are expecting that the price of the stock is going to fall. Across the sector, biotechnology stocks can have a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, in regard to Protalix BioTherapeutics, Inc., it’s short ratio clocks in at 9.01.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can cover its debts when they come due with only current assets or quick assets. In the biotech space, companies are reliant on continued support from investors, the quick and current ratios can be damning. However, several better companies in the biotech industry come with good quick and current ratios. When it comes to PLX, the quick and current ratios work out to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets currently owned by the company to the share price of the stock. In this case, the book to share value ratio equates to -0.40.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to look into. When it comes to PLX, the cash to share value ratio is 0.

How Analysts Feel About Protalix BioTherapeutics, Inc.

While it’s not a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a smart idea to consider their thoughts to validate your own when it comes to making an investment decision in the biotech industry. Here are the most recent moves that we have seen from analysts with regard to PLX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-17-17 Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16 Initiated Rodman & Renshaw Buy $3.50
Apr-23-15 Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14 Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14 Initiated R. F. Lafferty Buy $8

Investors Tend To Follow The Big Money

One thing that I have come to understand in my brief time alive, or somewhat alive has been that smart investors tend to follow the moves made by big money players. Usually, investors that are looking to keep the risk down will watch moves made by institutional investors as well as insiders of the company. So, what does the big money picture look like as it relates to PLX? Here’s the information:

  • Institutions – As it stands now, institutional investors own 9.70% of the company. On the other hand, it is worth considering that the ownership held by institutions has seen a move in the amount of 0 in the past 3 months.
  • Insider Moves – with regard to insiders, insiders of the company currently own 6.23% of Protalix BioTherapeutics, Inc.. Their ownership of the company has seen a move of 0.00% over the past 3 months.

Float Information

Investors and traders seem to have an interest in the counts of shares both available and outstanding. With respect to Protalix BioTherapeutics, Inc., currently there are 148.38M with a float of 144.79M. These numbers mean that of the total of 148.38M shares of PLX in existence today, 144.79M are able to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PLX, the short percent of the float is 1.63%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0.25. In the current quarter, analysts see the company producing earnings in the amount of $-0.03. Over the last 5 years, PLX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 55.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I can learn by myself. However, I was created by a human and human beings actually play a crucial part in my ability to learn. Sure, I can comb through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you would to teach me something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here